Chirurgia (Bucur). 2021 Mar-Apr;116(2):170-177. doi: 10.21614/chirurgia.116.2.170.
Breast cancer represents one of the three most common gynecological cancers, with each subtype having distinct risk profile and treatment strategies. Optimal therapy for each case depends not only on tumor subtype and cancer stage, but also on patient preferences. Thus, the final therapeutic choice seems complicated to be reached. In addition, frequent relapses and the aesthetic effects have led to the search for more effective and less invasive methods. Surgical interventions have become less complex and new hormonal and chemotherapeutic drugs are established, that promise great results, either combined to surgical treatment or used exclusively. Luteolin is a representative of natural flavonoid that has proven to modulate various signaling pathways involved in cancer development. Recent data demonstrate that luteolin induces apoptotic cell death via antioxidant activity, acting as an anticancer agent against various types of human malignancies including breast cancer. The aim of this review is to summarize latest data considering the therapeutic role of luteolin in breast cancer.
乳腺癌是三种最常见的妇科癌症之一，每种亚型都有不同的风险特征和治疗策略。每个病例的最佳治疗不仅取决于肿瘤亚型和癌症分期，还取决于患者的偏好。因此，最终的治疗选择似乎很难确定。此外，频繁的复发和美容效果促使人们寻找更有效和微创的方法。手术干预变得不那么复杂，新的激素和化疗药物已经确立，它们承诺能取得很好的效果，无论是与手术治疗联合使用还是单独使用。木樨草素是一种天然类黄酮的代表，已被证明可以调节参与癌症发展的各种信号通路。最近的数据表明，木樨草素通过抗氧化活性诱导细胞凋亡死亡，作为一种抗癌剂，对包括乳腺癌在内的多种人类恶性肿瘤具有作用。本综述的目的是总结最新数据，探讨木樨草素在乳腺癌中的治疗作用。
